EPRX Eupraxia Pharmaceuticals Inc.
$7.08▲ +3.36%
Healthcare
Other
After hours
$7.08▲ +0.00%
Oct 27, 4:00 PM ET
Volume 485.0K
Avg Volume (10D) 594.4K
Key Metrics & Fundamentals
Market Cap
$467.80M
P/E Ratio
–
Div Yield
0.00%
52W Range
5.25 - 9.32
% vs 50 MA
-6.55%
% vs 200 MA
-3.35%
RSI-14
45.9
MACD Histogram
-0.0200
Beta (1Y vs SPY)
1.58
Free Cash Flow
-$13.27M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$20.35M
COGS
–
Operating Exp
$18.10M
Operating Income
-$18.10M
EBIT
-$18.10M
Pretax Income
-$14.46M
Net Income
-$14.49M
EPS (Diluted)
-0.23
Price & Volume History
Loading chart…
Recent News
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
GlobeNewswire · Oct 22, 2026 8:30 AM ET
Eupraxia Pharmaceuticals Says Phase 2b Trial in Eosinophilic Esophagitis Meets Enrollment Target
MT Newswires · Oct 15, 2026 8:46 AM ET
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
GlobeNewswire · Oct 15, 2026 8:00 AM ET
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
GlobeNewswire · Oct 9, 2026 8:00 AM ET
Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients
MT Newswires · Sep 30, 2026 12:27 PM ET
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
GlobeNewswire · Sep 30, 2026 8:00 AM ET
Wedbush Initiates Eupraxia Pharmaceuticals at Outperform With $17 Price Target
MT Newswires · Sep 24, 2026 7:04 AM ET
Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice
Insider Monkey · Sep 12, 2026 3:56 AM ET
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
GlobeNewswire · Sep 8, 2026 8:00 AM ET
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
GlobeNewswire · Aug 13, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See EPRX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.